Gooderham Melinda J, Poulin-Costello Melanie, Shelton Jennifer, Bayan Nabil, Papp Kim A
Skin Centre for Dermatology, Peterborough, Ontario, Canada
Amgen Canada Inc, Mississauga, Ontario, Canada.
J Cutan Med Surg. 2016 Mar-Apr;20(2):106-12. doi: 10.1177/1203475415604322. Epub 2015 Sep 1.
The factors influencing the use of topical agents in combination with biologic therapies for the treatment of plaque psoriasis (PsO) are not well understood.
To examine potential predictors of topical use in patients with moderate to severe plaque PsO receiving etanercept (ETN).
Post hoc descriptive analyses and a multinomial regression of the REFINE study data were used to examine associations between topical agent potency and covariates, including Psoriasis Area and Severity Index (PASI) score, study site, and province.
Not achieving PASI 90 at week 12 predicted topical use, with a lower PASI 90 rate in patients who used high-potency topical agents post randomization (P = .003). Additionally, statistically significant differences were found in patterns of topical use among Canadian provinces (P = .007), with the use of high-potency topical agents being greater in Ontario and Quebec than the rest of Canada.
This analysis revealed that region and PASI 90 status at week 12 predict topical use.
影响局部用药联合生物疗法治疗斑块状银屑病（PsO）的因素尚未完全明确。
探讨接受依那西普（ETN）治疗的中度至重度斑块状PsO患者局部用药的潜在预测因素。
使用REFINE研究数据进行事后描述性分析和多项回归分析，以研究局部用药效力与协变量之间的关联，包括银屑病面积和严重程度指数（PASI）评分、研究地点和省份。
第12周未达到PASI 90可预测局部用药情况，随机分组后使用高效局部用药的患者PASI 90达标率较低（P = 0.003）。此外，加拿大各省在局部用药模式上存在统计学显著差异（P = 0.007），安大略省和魁北克省使用高效局部用药的情况多于加拿大其他地区。
该分析表明，第12周时的地区和PASI 90状态可预测局部用药情况。
